Transmissibility, infectivity, and immune resistance of the SARS-CoV-2 BA.2.86 variant

Keiya Uriu(National Institute of Infectious Diseases), Kei Sato(University of Tokyo Hospital)
bioRxiv (Cold Spring Harbor Laboratory)
September 7, 2023
10.1101/2023.09.07.556636
Cited by 9

Related Papers

Attenuated fusogenicity and pathogenicity of SARS-CoV-2 Omicron variant
|Nature|2022|748
Enhanced fusogenicity and pathogenicity of SARS-CoV-2 Delta P681R mutation
|Nature|2021|680
SARS-CoV-2 ORF3b Is a Potent Interferon Antagonist Whose Activity Is Increased by a Naturally Occurring Elongation Variant
|Cell Reports|2020|438
An emerging SARS-CoV-2 mutant evading cellular immunity and increasing viral infectivity
|bioRxiv (Cold Spring Harbor Laboratory)|2021|74
Virological characteristics of the SARS-CoV-2 Omicron BA.2.75
|bioRxiv (Cold Spring Harbor Laboratory)|2022|44